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FK 506 (Tacrolimus-Prograf) was first used clinically in February 1989. 1 and approved by the United States 
Food and Drug Administration in April 1994 as a new 
immunosuppressive agent for use after liver transplanta-
tion.::- 4 It has also been utilized as the primary immuno-
suppressive agent after heart.s lung/' intestinal.7 and isletS 
transplantation. In renal transplantation. it has been stud-
ied extensively as a primary and rescue agent in adults and 
children at a single center. the University of Pittsburgh9 - '2; 
it also has been studied as a primary agent in multicenter 
trials in Japan. Europe. and the United States. 13•14 The 
most recent publications from the University of Pittsburgh 
have reported on a prospective. randomized trial comparing 
two FK 506-based regimens. with and without azathio-
prine. 10 This report presents. for the first time. results with 
all 397 cases entered into this trial. 
PATIENTS AND METHODS 
Between August 1. 1991. and December 9. 1993. a total of 395 
patients undergoing 397 renal transplants were entered into a 
prospective. randomized trial comparing FK 506/prednisone and 
FK 506/azathioprine/prednisone (Table 1). The details of random-
ization. the immunosuppressive protocols. and the inclusion and 
exclusion criteria have been previously described: the only addi-
tional exclusion criterion was for four patients who were undergo-
ing their third or fourth transplant after October 11. 1992. and who 
received FK 506. prednisone. and 1 week of cyclophosphamide as 
part of a pilot trial. The mean recipient age was ~.6 :!: 14.1 years 
Table 1. Recipient and Donor Demographics 
FK 506IPrednisone FK 506/ AzaiPred Total 
Patients 198 197 395 
Transplants 199 198 397 
Recipient age (yrs) 43.6:!: 14.0 45.7 = 14.1 44.6:!: 14.1 
Range (17.3-72.8) (17.4-78.0) (17.3-78.0) 
First transplant 147 (74%) 150 (76%) 297(75%) 
Retransplant 52 (26%) 48(24%) 100 (25%) 
PRA ~ 40% 25(13%) 28 (14%) 53(13%) 
Age ~ 60 31 (16%) 41 (21%) 72(18%) 
Black 23 (12%) 28 (14%) 51 (13%) 
Donor age (yrs) 35.3 = 19.8 32.7 = 21.2 34.0 = 20.5 
Range (0.1-69.0) (0.1-75.0) (0.1-75.0) 
Cold ischemia time 31.6=8.6 31.4 = 9.4 31.5 :!: 9.0 
(hrs) 
Cadaver 173(87%) 185(93%) 358(90%) 
Living donor 26(13%) 13(7%) 39(10%)· 
En bloc 19 (11%) 31 (17%) 50(14%) 
HLA match 2.7=1.4 2.5:!: 1.3 2.6:t 1.3 
HLA mismatch 3.0 = 1.5 3.0:: 1.4 3.0:t 1.4 
'p < .04. 
814 
(range 17.3 to 78.0). One hundred (25%) patients were undergoing 
retransplantation. and 53 (13%) had panel reactive antibod~ 
(PRA) levels greater than 40%. There were 72 (18%) recipient~ 
over 60 years of age at the time of transplantation. and 61 (15%) 
were either black (51% to 13%), Hispanic (6% to 2%), or Asian 
(4% to 1%). The most common cause of end-stage renal disease 
was diabetes mellitus. which accounted for 98 (25%) cases. 
The mean donor age was 34.0 :!: 20.6 years (range 0.1 to 75.0). 
There were 39 (10%) living donors. Fifty (14%) of the cadaveric 
cases were with pediatric en bloc kidneys from donors 3 years of 
age or younger. The mean cold ischemia time was 31.5 :!: 9.0 hours. 
The mean number of HLA matches and mismatches was 2.6 :!: 1.3 
and 3.0 :!: 1.4: there were 18 (5%) 6-antigen match. and 30 (l;C,) 
O-antigen mismatch cases. 
No significant differences existed between the double and triple 
therapy group with regard to the recipient and donor charactcTls-
tics. with one exception: there were more living donor cases in the 
double therapy group (13% vs 7%. P = .03). 
Statistical Analysis 
The standard two-sample t test was used to test differences in 
means. while differences in proportions were tested using Pearson's 
chi-square test of association. 
Patient survival was calculated from the date of kidney trans-
plantation until death. and graft survival from the date of kidney 
transplantation until graft failure. retransplantation. or patient 
death. Survival curves were generated using the Kaplan-Meier 
(product-limit) method and were compared using the generalized 
Wilcoxon (Breslow) test. A multivariate Cox's regreSSion analysis 
was performed using a stepwise procedure to identify high-ri~1-. 
patients for graft failure. A P-value less than .05 was considered 
statistically significant. All analyses were performed according to 
intention-to-treat. unless otherwise stated. 
This trial was approved by the Institutional Review Board of the 
University of Pittsburgh. 
RESULTS 
The mean follow-up was 20.0 :!: 8.3 months (range 6.7 to 
35.0). The overall 1- and 2-year actuarial patient survival 
was 95% and 93%. The overall 1- and 2-year actuarial graft 
survival was 89% and 83% (Fig 1). There was no difference 
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Fig 1. Actuarial patient and 
graft survival. 
Table 2, Actuarial Survival Data 
in patient survival between the double and triple therapy 
groups, nor was there any difference in graft survival. For 
first cadaver transplants, the 1- and 2-year graft survival was 
91 % and 82%. Graft survival in selected subgroups is shown 
in Table 2. There was no difference in outcome between 
primary and retransplantation. low and high PRA patients, 
blacks and non-blacks. and patients under or over 60 years 
of age. Patients experiencing acute rejection after trans-
plantation had a 1- and 2-year graft survival of 87% and 
79%, respectively, while patients not experiencing rejection 
had a 1- and 2-year graft survival of 91 % and 86% (P = 
NS). 
A multivariate analysis was performed to identify specific 
factors associated with an increased risk of graft failure, and 
the only significant variable was the presence or absence of 
initial graft function. The \- and 2-year actuarial graft 
survival for patients with initial function was 94% and 89%. 
respectively, while that for patients without initial function 
was 78% and 71 % (relative risk 3.53, P < .0001. range 2.09 
to 5.91). 
The mean serum creatinine was 2.0 ::!: 1.1 mg/dL. and the 
calculated creatinine clearance was 56 ::!: 27 mUmin. The 
mean BUN was 32 ::!: 16 mg/dL. No differences existed 
between the two groups with regard to these parameters. 
The incidence of acute rejection was 49%, and was higher 
in the double therapy than in the triple therapy group (54% 
vs 44%, P < .05). The incidence of steroid-resistant rejec-
tion requiring OKT3 or ATG was 10%, and again was 
higher in the double therapy group than in the triple 
therapy group (14% vs 7%, P < .04). A multivariate analysis 
revealed several risk factors for rejection. including double 
therapy (relative risk 1.68, range 1.10 to 2.55, P < .02); 
cadaveric donor (relative risk 2.18, range 1.06 to 4.50, P < 
.04): black recipient (relative risk 3.14, range 1.62 to 6.13. 
Patient survival 
1 yr 
2 yr 
Graft survival overall 
1 yr 
2 yr 
First Cadaver 
1 yr 
2 yr 
Retransplant 
1 yr 
2 yr 
PRA <! 40% 
1 yr 
2 yr 
Age <! 60 
1 yr 
2 yr 
Black 
1 yr 
2 yr 
Rejection 
1 yr 
2 yr 
No rejection 
1 yr 
2 yr 
ATN 
1 yr 
2 yr 
No ATN 
1 yr 
2 yr 
'p < .0001. 
FK 5061Prednisone FK 506/Aza/Pred Total 
(%) (%) (%) 
97 94 95 
95 90 93 
90 88 89 
86 79 83 
90 91 91 
85 79 82 
88 77 83 
86 75 80 
92 82 87 
92 78 85 
87 88 87 
83 71 75 
96 82 88 
84 66 74 
88 86 87 
84 73 79 
92 89 91 
89 84 86 
80 76 78' 
76 64 71 
95 94 94 
92 87 89 
l 
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P < .001); PRA > 40% (relative risk 2.02, range 1.01 to 
4.03, P < .03); and recipient age over 60 (relative risk 0.51. 
range 0.20 to 0.88, P < .02). In spite of their higher risk of 
rejection. and the reduction of this risk by triple drug 
therapy, there was a paradoxical trend (NS) to better results 
in black patients treated with the two drug regimen (Table 
1 ). 
The incidence of initial nonfunction andlor requirement 
for dialysis in the first week after transplantation was 35%. 
and this was not significantly different between the two 
groups. 
The incidence of cytomegalovirus disease or infection 
was 16% and was not different between the double and 
triple therapy groups. 
The incidence of posttransplant Iymphoproliferative dis-
order (PTLD) was 1 %. There were 5 cases of PTLD, 3 in 
the double therapy group, and 2 in the triple therapy group. 
All cases of PTLD resolved after reduction or cessation of 
immunosuppression and treatment with gancyclovir. One 
patient lost his allograft. In addition. there was one case of 
Kaposi's sarcoma in a patient on triple therapy who had 
been temporarily lost to follow-up. The lesion resolved after 
cessation of immunosuppression, but the allograft was 
eventually lost. 
The incidence of initial new onset diabetes mellitus was 
18%; over 40% of these patients were able to be weaned off 
insulin after the dosages of FK 506 and steroids were 
reduced. and the final incidence of new onset diabetes was 
10%. There was no difference between double and triple 
therapy. 
The mean FK 506 dosage was 0.15 :!: 0.12 mg/kg per day 
at most recent follow-up, and the mean FK 506 plasma level 
was 0.83 :!: 0.60 ng/mL. No significant differences existed 
between the double and triple therapy groups with regard 
to these parameters. 
Forty-nine percent of successfully transplanted patients 
have been weaned 01I prednisone. The mean prednisone 
dose was 3.8 :!: 5.2 mgtd; for those patients still on 
prednisone. the mean dose was 7.4 :!: 5.0 mg/d. 
The mean azathioprine dose in the patients on triple 
therapy was 84 :!: 41 mgtd, or l.l :!: 0.5 mg/kg per day. 
Thirty-nine (20%) patients randomized to double ther-
apy had azathioprine added to their immunosuppressive 
regimen at one time or another because of rejection. and 33 
( 17%) have remained on triple therapy. A total of III 
(56%) patients randomized to triple therapy had azathio-
prine discontinued at one time or another, and 79 (40%) 
have remained on double therapy. The overall final inci-
dence of crossover was thus 28%. Patient and graft survival 
after crossover were comparable between the two groups. 
The mean serum cholesterol was 195 :!: 49 mg/dL and 
was not different between the two groups. 
Thirty-five percent of patients are off antihypertensive 
medications, and another 39% are taking one antihyperten-
sive medication. There was no difference between double 
and triple therapy. 
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DISCUSSION 
This paper presents data on the largest number of renal 
transplant recipients to date receiving FK 506 as the 
primary immunosuppressive agent. The data confirm and 
extend recent reports on the excellent outcomes achievable 
with this agent. lO- 12 One- and 2-year actuarial patient 
survival of 95% and 93%, and 1- and 2-year actuarial graft 
survival of 89% and 83%, respectively, have been obtained. 
and 49% of the successfully transplanted recipients have 
been weaned off prednisone. A previously reported trend 
toward inferior results under triple therapy was still evi-
dent,1O but this was no longer significant in the analysis of 
the larger group. The only difference associated with triple 
therapy was a slightly lower incidence of rejection, both 
steroid-sensitive and steroid-resistant. These data, together 
with the crossover incidence from double to triple therapy 
of 17%, suggest that there are a number of patients who can 
benefit from azathioprine as a third agent with FK 506. 
Unfortunately, both the high crossover incidence from 
triple to double therapy of 40% and the overall lack of 
improved patient or graft survival in the triple therapy 
group raise questions about the overall benefit of azathio-
prine with FK 506. We are at present evaluating the role of 
a short course of cyclophosphamide with FK 506 and 
steroids in an effort to abort cryptic or anamnestic antibody-
mediated rejection, which is known to be nonresponsive to 
FK 506.9 •15 As new immunosuppressive agents designed to 
replace azathioprine, such as Mycophenolate Mofetil,16 
Brequinar,17 or other new agents, including RapamycinlS 
and Leflunomide,19 become available, it will be worthwhile 
to evaluate them in combination with FK 506. 
The toxicities of FK 506 have been well-described and 
include nephrotoxicity/~o-24 neurotoxicity,ls and diabetoge-
nicity;z6 all of the side effects have been seen to a compa-
rable degree with conventional cyclosporine-based regi-
mens. For the same degree of toxicity, we have seen better 
outcomes under FK 506-based therapy than under cyclo-
sporine-based regimens. 
[n summary, FK 506 is an effective immunosuppressive 
agent in patients undergoing kidney transplantation and is 
associated with 1- and 2-year actuarial patient survival of 
95% and 93%, and 1- and 2-year actuarial graft survival of 
89% and 83%, respectively. Also, 49% of successfully 
transplanted patients have been weaned off steroids. The 
addition of azathioprine resulted in comparable patient and 
graft survival, and somewhat less rejection, but with a need 
to discontinue the agent in 40% of cases. The effect of other 
third agents will be investigated as they become available. 
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